Google Alert - "Myeloproliferative neoplasms" OR "polycythemia vera" OR myelofibrosis OR "essential thrombocythemia" · Scour

FDA Approves Ruxolitinib Tablets in Hematologic Malignancies

Novartis Korea's Jakavi wins reimbursement for 2nd-line treatment of polycythemia vera

Exelon Corporation (EXC) ComEd Reconciliation Filing to Match Cost with Revenues for ...

Neurocrine Biosciences, Inc (NASDAQ

Incyte Announces Fda Approval of Jakafi Xr Extended-Release Tablets for the Treatment of ...

One pill a day: FDA approves Incyte's Jakafi XR for 3 conditions

FDA Clears Once-Daily Ruxolitinib Tablets for Myelofibrosis , Polycythemia Vera , and GVHD

Incyte : FDA Approves Jakafi XR In Myelofibrosis , Polycythemia Vera , And Graft-Versus-Host Disease

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for ...

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for ...

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for ...

Myelofibrosis (MF) in 2026: Matching Therapy to the Dominant Clinical Problem

12 Press Releases You Need to See This Week

Lilly To Acquire Ajax for $2.3 Bn

Role of Chitinase 3-like-1 in Myelofibrosis via Fibroblast-Produced Extracellular Matrix Enhancement

FDA backs Phase 2b amsulostat trial; key clinical data and milestones expected in 2026

Exclusive BAC Article: Protagonist Therapeutics; FDA Approval ICOTYDE Plaque Psoriasis ...

Syntara Secures A$10 Million Capital Injection to Advance Clinical Programs

First Marrow and Leukemia Symposium in the Midwest Brings National Experts to Detroit

Syntara raising $10m to advance myelofibrosis drug toward Phase 2b trial

Log in to enable infinite scrolling